Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A
Rhea-AI Filing Summary
Cytek Biosciences, Inc. received an amended Schedule 13G/A disclosing significant ownership positions by Millennium-affiliated entities and Israel A. Englander. Integrated Core Strategies (US) LLC reports beneficial ownership of 7,162,923 shares of common stock, representing 5.5% of the class, all with shared voting and dispositive power. Millennium Management LLC, Millennium Group Management LLC, and Mr. Englander each report beneficial ownership of 9,338,010 shares, or 7.2% of the class, also solely through shared voting and dispositive power. The filing explains that the securities are held by entities subject to voting control and investment discretion of Millennium Management LLC and related managers, and it includes language that this structure should not, by itself, be construed as an admission of beneficial ownership by these reporting persons.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned financial
investment discretion financial
AI-generated analysis. How Rhea-AI works. Not financial advice.